Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effectiveness of low-molecular-weight heparin for prevention of deep venous thrombosis after surgery for colorectal cancer in Japanese patients: a randomized controlled phase III trial

ABSTRACT: Interventions: low-molecular-weight heparin after surgery no treatment Primary outcome(s): The efficacy of low-molecular-weight heparin to prevent deep venous thrombosis after surgery for colorectal cancer Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2645751 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Hepatic FGFR-ERK-HRG axis regulates heparin-induced thrombocytopenia with thrombosis

Project description:To identify key plasma proteins altered by heparin challenges and determine its regulatory roles in pathogenic immune complexes formation and thrombosis in HIT

2026-06-30 | GSE318282 | GEO

Hepatic FGFR-ERK-HRG axis regulates heparin-induced thrombocytopenia with thrombosis

Project description:To identify key plasma proteins altered by heparin challenges and determine its regulatory roles in pathogenic immune complexes formation and thrombosis in HIT

2026-06-30 | GSE318200 | GEO

Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer

Project description:The chemoprophylaxis of deep vein thrombosis (DVT) with subcutaneous low-molecular-weight heparin (enoxaparin) in the postoperative period of elective surgeries is already well established in the literature and in clinical practice. However, the use of this medication can have a financial impact on the patient and the parenteral presentation itself is associated with pain at the application site, which can make it difficult for patients to adhere.

| 2711239 | ecrin-mdr-crc

Hepatic FGFR-ERK-HRG axis regulates heparin-induced thrombocytopenia with thrombosis

Project description:Hepatic FGFR-ERK-HRG axis regulates heparin-induced thrombocytopenia with thrombosis

| PRJNA1416902 | ENA

Hepatic FGFR-ERK-HRG axis regulates heparin-induced thrombocytopenia with thrombosis

Project description:Hepatic FGFR-ERK-HRG axis regulates heparin-induced thrombocytopenia with thrombosis

| PRJNA1418514 | ENA

A targetable pathway in neutrophils mitigates both arterial and venous thrombosis

Project description:Arterial and venous (A/V) thrombosis constitutes the greatest source of morbidity and mortality worldwide. Long considered as distinct entities, accumulating evidence indicates that A/V thrombosis can occur in the same populations suggesting that common mechanisms are likely operative. Although hyperactivation of the immune system is a common forerunner to the genesis of thrombotic events in both vascular systems, the key molecular control points remain poorly understood. Consequently, anti-thrombotic therapies targeting the immune system for therapeutic gain are lacking. Here we show that neutrophils are key effectors of both A/V thrombosis and can be targeted via novel immunoregulatory nanoparticles. Using antiphopholipid antibody syndrome (APS) as a model for devastating A/V thrombosis, we identified the transcription factor Krüppel-like factor 2 (KLF2) as a key regulator of neutrophil activation. Upon activation via genetic loss of KLF2 or administration of antiphospholipid antibodies, neutrophils cluster P-selectin glycoprotein ligand 1 (PSGL-1) via cortical actin remodeling, thereby increasing adhesion potential at thrombosis sites. Targeting clustered PSGL-1 using designer nanoparticles attenuates neutrophil-mediated A/V thrombosis in APS and KLF2 knockout models, illustrating the importance and feasibility of targeting activated neutrophils to prevent pathological thrombosis. Together, our results demosntrate a role for activated neutrophils to prevent pathological thrombosis. Together, our results demonstrate a role for activated neutorphils in both arterial and venous thrombosis and identify key molecular events that serve as potential targets for therapeutics against diverse causes of immunothrombosis.

2022-09-12 | GSE208336 | GEO

Interactive relationships between potential miRNAs and target mRNAs in deep venous thrombosis identified by RNA sequencing

Project description:Background: Deep venous thrombosis is one of the most common peripheral vascular diseases that lead to major morbidity and mortality. We aimed to identify potential differentially expressed miRNAs and target mRNAs, which were helpful in understanding the potential molecule mechanism of deep venous thrombosis.

2025-02-01 | GSE196751 | GEO

Epigenetic metabolite lipid nanoparticles alleviate venous thrombosis via bone marrow reprogramming

Project description:Targeting coagulation cascade is a mainstay approach to therapy of thrombosis. One of the most prevalent complications of anticoagulation is a significant bleeding risk that can result in hospitalization. Recent studies on immunothrombosis (i.e. inflammation-linked thrombosis) proposed myeloid cells, especially neutrophils, to actively participate in thrombus formation through neutrophil extracellular traps (NETosis) and activation of inflammatory pathways. Here, we developed lipid nanoparticles (LNPs) with coagulation cascade-independent action that target neutrophils to alleviate venous thrombosis. A single intravenous dose of immunomodulatory metabolite itaconate (ITA)-bearing LNPs (ITA-LNPs) targeted >90% of bone marrow-resident neutrophils, but not macrophages or T lymphocytes. ITA-LNPs significantly diminished inflammation in cultured neutrophils and macrophages and improved survival in the mouse model of endotoxemia. When tested in an inferior vena cava ligation model of deep vein thrombosis, ITA-LNPs decreased the size and weight of thrombi as compared to control LNPs (Ctrl-LNPs). In addition, the thrombi from ITA-LNPs injected mice had significantly reduced neutrophil infiltration, decreased NETosis and interleukin-1 beta (IL-1β) expression. Intriguingly, one of the mechanisms through which this occurred was histone H4K12ac deacetylation, resulting in chromatin condensation and transcriptional repression of inflammatory genes and transcription factors involved in DNA damage response. Finally, we found that ITA-LNPs were hemostatically safe and neither targeted nor activated platelets in vivo. In sum, our work explores an LNP technology with an epigenetic mode of action serving as an anti-immunothrombotic therapy that could improve clinical outcomes without additional hemorrhagic risk.

2025-07-18 | GSE283897 | GEO

GENEVA GWAS of Venous Thrombosis

Project description:GENEVA GWAS of Venous Thrombosis

| PRJNA75937 | ENA

Single-cell RNA sequencing on the vein wall of mouse deep vein thrombosis

Project description:Deep vein thrombosis (DVT) is a common clinical problem, but its cellular and molecular mechanisms remain incompletely understood. We performed single-cell RNA sequencing (scRNA-seq) on the vein wall of mouse inferior vena cava (IVC) ligation model of deep vein thrombosis (DVT), to analyze the transcriptomic changes in the vein wall during acute venous thrombosis.

2023-02-10 | GSE221978 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data